Actavis PLC (NYSE:ACT)

During the Trading Day
296.23 -1.08 / -0.36%
As of 4:03pm ET
Day’s Change
During After-Hours   Switch to standard view »
296.23 0.00 / 0.00%
Volume: 22.8K
Actavis' Xydalba Granted Marketing Authorisation in Europe - Analyst Blog
3:17pm /
Actavis Barred from Selling Generic Pulmicort Respules - Analyst Blog
Feb 18 /
Jim Cramer: I'm Making My Peace With This Happy Market
12:58pm /
Teva to Commercialize Eagle's Cancer Drug in the U.S. - Analyst Blog
Feb 18 /
Actavis's $21bn bond sale is second-largest on record
12:28pm /
Actavis Beats on Q4 Earnings, Allergan Acquisition on Track - Analyst Blog
Feb 18 /
11 stocks hedge funds and mutual funds love now
Mar 02 /
Actavis (ACT) Beats on Q4 Earnings & Revenues - Tale of the Tape
Feb 18 /
3 Stocks Moving The Drugs Industry Upward
Mar 02 /
Can Actavis (ACT) Keep the Earnings Streak Alive in Q4? - Analyst Blog
Feb 17 /
Actavis' Infectious Disease Product, Avycaz, Gets FDA Nod - Analyst Blog
Feb 26 /
Is a Surprise Coming for Actavis (ACT) This Earnings Season? - Tale of the Tape
Feb 17 /
3 Stocks Dragging The Drugs Industry Downward
Feb 24 /
Healthcare: The race to cure rising drug costs
Feb 10 /
Jim Cramer Says Investors Should Buy Valeant Pharmaceuticals (VRX) After It Acquired ...
Feb 24 /
Pharma takes a dose of sense from the deals doctor
Feb 06 /
Valeant Pharma (VRX) Soars on Salix Buy: 3 Keys for Investors - Stocks in the News
Feb 23 /
AstraZeneca to pay $600m for Actavis respiratory drug arm
Feb 05 /
Billionaire George Soros Just Bought These 3 Stocks: Should You?
Feb 21 /
Ackman's Pershing Square secures seat on Zoetis board
Feb 04 /

To view my watchlist

Not a member yet?

Sign up now for a free account